Las Vegas, NV -- (SBWIRE) -- 12/12/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: CytRx Corporation (NASDAQ:CYTR), Cereplast Inc (OTCMKTS:CERP), BG Medicine, Inc. (NASDAQ:BGMD), Gevo, Inc. (NASDAQ:GEVO)
CytRx Corporation (NASDAQ:CYTR) managed to keep its gain at 68.20% on above-normal volume of 31.83M shares. The stock settled at $4.02 after floating in a range of $3.45 to $34.38. Its latest price has reached market capitalization of $168.74 million. Its 52-week range has been $1.80 to $4.38. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate.
Has CYTR Found The Bottom and Ready To Move Up? Find Out Here
Cereplast Inc (OTCMKTS:CERP) traded up on a volume of 27.15 million, higher than its standard daily volume. Shares have gained 9.26% to $0.00059. Over the last twelve months, the stock has lost-92.29% and faced a worst price of $0.01. Cereplast, Inc. (Cereplast) is engaged in developing and commercializing bio-based resins through two product families: Cereplast Compostables Resins, which are compostable, renewable, ecologically sound substitutes for petroleum-based plastics, and Cereplast Sustainables resins (including the Cereplast Hybrid Resins product line), which replaces up to 90% of the petroleum-based content of traditional plastics with materials from renewable resources.
For How Long CERP’s Gloss will Attract Investors? Find out via this report
BG Medicine, Inc. (NASDAQ:BGMD) settled 30.56% higher at $1.41 on above-normal volume of 21.16M shares during the last trading day. The stock has its 12-month high at $4.48 and 52-week low price was $0.55. It traded in a range of $1.27 to $1.70 during the last trading day. BG Medicine, Inc. (BG Medicine) is a life sciences company focused on the discovery, development and commercialization of cardiovascular diagnostics to addresses unmet medical needs. The Company focuses on blood-based tests. Its lead product candidate in development is CardioSCORE, which is a multi-analyte biomarker-based blood test for atherothrombotic cardiovascular disease, commonly known as vulnerable plaque. In March 2011, the Company entered into a supply agreement with Health Diagnostic Laboratory, Inc. (HDL), pursuant to which HDL agreed to purchase manual galectin-3 test kits from the Company and to offer galectin-3 testing services to physicians in the United States.
Why Should Investors Buy BGMD After the Recent Fall? Just Go Here and Find Out
In the last trading session, Gevo, Inc. (NASDAQ:GEVO) was down on high volume, trading at a volume of 7 16.78M versus its average daily volume of 1.08 million shares. At $1.21, the stock has attained market capitalization of 57.09 million. Gevo, Inc., is a renewable chemicals and advanced biofuels company. The Company is focused on the development and commercialization of alternatives to petroleum-based products. The Company operates in two segments: Gevo, Inc. Segment and Gevo Development/Agri-Energy Segment. Gevo, Inc. Segment is responsible for all research and development activities related to the future production of isobutanol, maintaining and protecting its intellectual property portfolio,
Why Should Investors Buy GEVO After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)